DALLAS, July 29, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/AEZS
AEZS has been relatively stable recently. This is evidenced by the width of its Bollinger Bands which are tighter than normal. Additionally, AEZS is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
AEterna Zentaris Inc. (AEZS) is a global biopharmaceutical company focused on endocrine therapy and oncology. The Company's product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The products of the Company include Cetrorelix, AEZS-108, Perifosine, Ozarelix, AEZS-112 and AEZS-130. On March 31, 2008, the Company completed the selling of the Company's product Impavido to Paladin Labs Inc. (Paladin). On March 5, 2009, the Company entered into a development, commercialization and license agreement with sanofi-aventis for the development, registration and marketing of Cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market.
Message Board Search for AEZS: http://www.boardcentral.com/boards/AEZS
In the report, the analyst notes:
"Revenues were $6.4 million for the three-month period ended March 31, 2010, compared to $6.1 million for the same period in 2009. The increase is mainly due to a comparative increase in sales of Cetrotide® to certain customers in the first quarter of 2010.
"AEZS recently announced that its partner, Keryx Biopharmaceuticals Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration ("FDA") for perifosine, the Company's novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma. Neuroblastoma is a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies."
To read the entire report visit: http://www.microstockprofit.com/lp/AEZS
See what investors are saying about AEZS at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.